康乃德生物医药宣布，其研发的Rademikibart 300毫克静脉推注剂型在针对哮喘及慢性阻塞性肺病（COPD）的临床研究中取得突破性进展。数据显示，该治疗方案能够促使患者第一秒用力呼气容积（FEV1）实现快速且显著的提升，改善幅度达到或超过200毫升。
这一结果凸显了Rademikibart在呼吸系统疾病治疗领域的潜在价值。FEV1作为衡量肺功能的关键指标，其快速改善对缓解患者症状、提升生活质量具有重要意义。研究证实，该药物通过静脉推注给药，起效迅速，为哮喘和慢阻肺患者提供了新的治疗选择。
康乃德生物医药将继续推进相关临床研究，深入探索Rademikibart的疗效与安全性，致力于为全球呼吸疾病患者带来更优的治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.